Transgenomic, Inc. (TBIO) Signs Commercialization Collaboration With PerkinElmer, Inc. (PKI) for Oncology Diagnostic Test Portfolio
11/1/2013 9:54:11 AM
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into a collaboration agreement with PerkinElmer, Inc.(NYSE:PKI) a global leader focused on improving the health and safety of people and the environment, to market and distribute Transgenomic’s oncology diagnostic test portfolio of products in territories outside the United States.
Help employers find you! Check out all the jobs and post your resume.
comments powered by